Gold prices edge higher on raised Fed rate cut hopes
LONDON - Poolbeg Pharma PLC (AIM:POLB), a clinical-stage biopharmaceutical company, has announced the release of its Annual Report and Accounts for the year ended December 31, 2024. The report, along with the notice of its upcoming Annual General Meeting (AGM), has been distributed to shareholders today.
The AGM is scheduled to take place at the offices of DAC Beachcroft LLP in London at 12 pm on June 23, 2025. Shareholders will have the opportunity to discuss the company’s performance and future plans at this meeting.
In addition to the Annual Report, Poolbeg Pharma has also issued a Circular detailing the Fundraising and convening a general meeting, which includes an accompanying form of proxy. Both the Annual Report and the Circular are available for download from the company’s official website.
Poolbeg Pharma focuses on developing innovative therapeutics to meet the unmet medical needs in various markets, including treatments for cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions such as obesity. The company is developing an oral encapsulated glucagon-like peptide GLP-1R agonist, among other clinical programs.
The announcement also contains forward-looking statements, which are based on assumptions about Poolbeg’s current and future business strategies and the environment in which it expects to operate. These statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those projected.
This news is based on a press release statement and has not been independently verified. The company advises that past performance should not be seen as an indication of future results, and no guarantee of future performance is provided. Investors are reminded that forward-looking statements are not guarantees of future performance and that actual events or results may differ significantly from those anticipated in such statements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.